These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 25073407)
21. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy. Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937 [TBL] [Abstract][Full Text] [Related]
22. Evaluating access to oral anti-diabetic medicines: A cross-sectional survey of prices, availability and affordability in Shaanxi Province, Western China. Yang C; Hu S; Zhu Y; Zhu W; Li Z; Fang Y PLoS One; 2019; 14(10):e0223769. PubMed ID: 31618273 [TBL] [Abstract][Full Text] [Related]
23. Pain Treatment Continues To Be Inaccessible for Many Patients Around the Globe: Second Phase of Opioid Price Watch, a Cross-Sectional Study To Monitor the Prices of Opioids. Pastrana T; Wenk R; Radbruch L; Ahmed E; De Lima L J Palliat Med; 2017 Apr; 20(4):378-387. PubMed ID: 27923102 [TBL] [Abstract][Full Text] [Related]
24. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006 [TBL] [Abstract][Full Text] [Related]
25. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India. Satheesh G; Sharma A; Puthean S; Ansil T P M; E J; Raj Mishra S; Unnikrishnan MK Trop Med Int Health; 2020 Dec; 25(12):1467-1479. PubMed ID: 32959441 [TBL] [Abstract][Full Text] [Related]
26. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America. Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770 [TBL] [Abstract][Full Text] [Related]
27. Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria. Orubu ESF; Robert FO; Samuel M; Megbule D Health Policy Plan; 2019 Dec; 34(Supplement_3):iii20-iii26. PubMed ID: 31816074 [TBL] [Abstract][Full Text] [Related]
28. Is the Brazilian pharmaceutical policy ensuring population access to essential medicines? Bertoldi AD; Helfer AP; Camargo AL; Tavares NU; Kanavos P Global Health; 2012 Mar; 8():6. PubMed ID: 22436555 [TBL] [Abstract][Full Text] [Related]
29. Pricing and availability of some essential child specific medicines in Odisha. Swain TR; Rath B; Dehury S; Tarai A; Das P; Samal R; Samal S; Nayak H Indian J Pharmacol; 2015; 47(5):496-501. PubMed ID: 26600637 [TBL] [Abstract][Full Text] [Related]
30. A national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri Lanka. Dabare PR; Wanigatunge CA; Beneragama BH BMC Public Health; 2014 Aug; 14():817. PubMed ID: 25103467 [TBL] [Abstract][Full Text] [Related]
31. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348 [TBL] [Abstract][Full Text] [Related]
32. Impact of National Drug Pricing Policy 2018 on access to medicines in Lahore division, Pakistan: a pre-post survey study using WHO/HAI methodology. Saeed A; Saeed H; Saleem Z; Yang C; Jiang M; Zhao M; Ji W; Aziz MM; Khan FU; Gillani AH; Atif N; Fang Y; Babar ZUD BMJ Open; 2020 Oct; 10(10):e034720. PubMed ID: 33033079 [TBL] [Abstract][Full Text] [Related]
34. Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu Province, China. Sun X; Wei J; Yao Y; Chen Q; You D; Xu X; Dai J; Yao Y; Sheng J; Li X BMJ Open; 2018 Oct; 8(10):e023646. PubMed ID: 30341137 [TBL] [Abstract][Full Text] [Related]
35. Enhancing medicine price transparency through price information mechanisms. Hinsch M; Kaddar M; Schmitt S Global Health; 2014 May; 10():34. PubMed ID: 24885767 [TBL] [Abstract][Full Text] [Related]
36. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. van Mourik MS; Cameron A; Ewen M; Laing RO BMC Cardiovasc Disord; 2010 Jun; 10():25. PubMed ID: 20534118 [TBL] [Abstract][Full Text] [Related]
37. Price discrimination in essential medicines: evidence from International Drug Price Indicator Guide data. Hanlon M; Zhang R Int Health; 2013 Mar; 5(1):58-63. PubMed ID: 24029847 [TBL] [Abstract][Full Text] [Related]
38. The prices people pay for medicines in Zimbabwe. Gavaza P; Simoyi T; Makunike B; Maponga CC Cent Afr J Med; 2009; 55(1-4):14-9. PubMed ID: 21977842 [TBL] [Abstract][Full Text] [Related]
39. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America. Moye-Holz D; Vogler S Appl Health Econ Health Policy; 2022 Jan; 20(1):67-77. PubMed ID: 34228312 [TBL] [Abstract][Full Text] [Related]
40. Prices, Availability and Affordability of Medicines with Value-Added Tax Exemption: A Cross-Sectional Survey in the Philippines. Lambojon K; Chang J; Saeed A; Hayat K; Li P; Jiang M; Atif N; Desalegn GK; Khan FU; Fang Y Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32708060 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]